Literature DB >> 21298365

CXCL12 G801A polymorphism is associated with an increased risk of benign salivary gland tumors in the Chinese population.

Weijia Liu1, Enxin Zhu, Ru Wang, Lihong Wang, Tingjiao Liu.   

Abstract

The chemokine CXCL12 and its receptor CXCR4 have been found to be important in tumor progression. A single-nucleotide polymorphism of CXCL12 G801A has been described and investigated in human immunodeficiency virus-1 (HIV-1) infection and in the susceptibility to several cancers. Here, we investigated the association between the CXCL12 G801A polymorphism and susceptibility to benign and malignant salivary gland tumors (SGTs) by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 102 Chinese SGT patients and 101 healthy controls. The frequencies of the AG (P = 0.001; odds ratio (OR), 3.764) and AA (P = 0.004; OR, 6.852) genotypes of CXCL12 were significantly higher in patients with benign SGTs than in the healthy controls. The frequency of the A allele of CXCL12 was also significantly higher in benign SGTs (P = 0.00; OR, 1.395) compared with the healthy controls. However, the AG (P = 0.171; OR, 3.163) and AA (P = 0.854; OR, 0.667) genotypes did not increase the risk of malignant SGTs significantly. The frequency of the CXCL12 A allele was also not found to be higher in malignant SGTs (P = 0.267; OR, 1.917) compared with the controls. Taken together, our results suggested that the CXCL12 G801A polymorphism is associated with an increased risk of benign SGTs, but not malignant SGTs, in the Chinese population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21298365     DOI: 10.1007/s12032-011-9838-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  37 in total

1.  Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression.

Authors:  Yu-Ping Jiang; Xiao-Hua Wu; Bin Shi; Wen-Xin Wu; Gui-Ran Yin
Journal:  Gynecol Oncol       Date:  2006-05-02       Impact factor: 5.482

2.  Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity.

Authors:  Maria De La Luz Sierra; Fuquan Yang; Masashi Narazaki; Ombretta Salvucci; David Davis; Robert Yarchoan; Hongwei H Zhang; Henry Fales; Giovanna Tosato
Journal:  Blood       Date:  2003-10-02       Impact factor: 22.113

3.  CXCL12-3' A polymorphism and lung cancer metastases protection: new perspectives in immunotherapy?

Authors:  Ana Coelho; Carmen Calçada; Raquel Catarino; Daniela Pinto; Graça Fonseca; Rui Medeiros
Journal:  Cancer Immunol Immunother       Date:  2005-09-06       Impact factor: 6.968

4.  CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia.

Authors:  Florence Dommange; Guillaume Cartron; Claire Espanel; Nathalie Gallay; Jorge Domenech; Lotfi Benboubker; Marc Ohresser; Philippe Colombat; Chistian Binet; Herve Watier; Olivier Herault
Journal:  FASEB J       Date:  2006-07-03       Impact factor: 5.191

5.  Stromal cell-derived factor-1 (SDF-1) alleles and susceptibility to breast carcinoma.

Authors:  Mahboobeh Razmkhah; Abdul-Rasoul Talei; Mehrnoosh Doroudchi; Tahereh Khalili-Azad; Abbas Ghaderi
Journal:  Cancer Lett       Date:  2004-12-13       Impact factor: 8.679

6.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.

Authors:  E Oberlin; A Amara; F Bachelerie; C Bessia; J L Virelizier; F Arenzana-Seisdedos; O Schwartz; J M Heard; I Clark-Lewis; D F Legler; M Loetscher; M Baggiolini; B Moser
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

7.  Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations.

Authors:  K Kas; M L Voz; E Röijer; A K Aström; E Meyen; G Stenman; W J Van de Ven
Journal:  Nat Genet       Date:  1997-02       Impact factor: 38.330

8.  A DNA polymorphism of stromal-derived factor-1 is associated with advanced stages of oral cancer.

Authors:  Eleftherios Vairaktaris; Antonis Vylliotis; Sofia Spyridonodou; Spyridoula Derka; Stavros Vassiliou; Emeka Nkenke; Christos Yapijakis; Zoe Serefoglou; Friedrich W Neukam; Efstratios Patsouris
Journal:  Anticancer Res       Date:  2008 Jan-Feb       Impact factor: 2.480

9.  Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo.

Authors:  Yan-Xi Sun; Jingcheng Wang; Charles E Shelburne; Dennis E Lopatin; Arul M Chinnaiyan; Mark A Rubin; Kenneth J Pienta; Russell S Taichman
Journal:  J Cell Biochem       Date:  2003-06-01       Impact factor: 4.429

10.  Plasma stromal cell-derived factor-1: host derived marker predictive of distant metastasis in breast cancer.

Authors:  Saima Hassan; Andrea Baccarelli; Ombretta Salvucci; Mark Basik
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

View more
  6 in total

1.  CXCL12 G801A polymorphism and cancer risk: An updated meta-analysis.

Authors:  Dan Meng; Yin-Xiang Wu; Vidhi Heerah; Shuang Peng; Meng-di Chu; Yong-Jian Xu; Wei-Ning Xiong; Shu-Yun Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

2.  Genome-wide association study identifies common genetic variants associated with salivary gland carcinoma and its subtypes.

Authors:  Li Xu; Hongwei Tang; Diane W Chen; Adel K El-Naggar; Peng Wei; Erich M Sturgis
Journal:  Cancer       Date:  2015-03-30       Impact factor: 6.860

3.  Analysis of the expression of SDF-1 splicing variants in human colorectal cancer and normal mucosa tissues.

Authors:  Risala Hussain Allami; Claudine Graf; Ksenia Martchenko; Beatrice Voss; Marc Becker; Martin R Berger; Peter R Galle; Matthias Theobald; Thomas C Wehler; Carl C Schimanski
Journal:  Oncol Lett       Date:  2016-01-25       Impact factor: 2.967

4.  The association between SDF-1 G801A polymorphism and non-small cell lung cancer risk in a Chinese Han population.

Authors:  Weiguo Xu; Rong Cui; Huapeng Yu
Journal:  Int J Clin Exp Med       Date:  2015-08-15

5.  Relationship between rs1801157 polymorphism in stromal cell-derived factor gene and systemic lupus erythematosus risk.

Authors:  Can Qian; Qinghua Zou; Yong Wang
Journal:  Oncotarget       Date:  2017-08-01

Review 6.  Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer.

Authors:  Franziska Eckert; Karin Schilbach; Lukas Klumpp; Lilia Bardoscia; Efe Cumhur Sezgin; Matthias Schwab; Daniel Zips; Stephan M Huber
Journal:  Front Immunol       Date:  2018-12-21       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.